Fibroscan & Serum Biomarkers: Advancing NAFLD Management

Assessing liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) is a critical aspect of treatment planning and prognostication. Traditionally, liver biopsy has been the go-to method for fibrosis assessment, but its invasiveness and limitations have led to the exploration of noninvasive alternatives. In recent years, two such alternatives have gained prominence: transient elastography, … Read more